Sangamo exits ST-920 gene therapy assets in Chapter 11 sale to PTC for USD 111 million

Bitget2026/09/21 20:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sangamo Therapeutics completed the sale of ST-920 Fabry gene-therapy assets to PTC Therapeutics on Sept. 17, 2026.
Consideration totaled USD 111 million in cash at closing.
Deal includes up to USD 100 million of milestone-based contingent payments.
PTC also assumed certain specified liabilities tied to the transferred assets.
Common stock remains suspended from Nasdaq trading, now quoted on OTCID Basic Market under symbol SGMOQ.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-396644), on September 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sangamo exits ST-920 gene therapy assets in Chapter 11 sale to PTC for USD 111 million

You may also like

Crypto prices